![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 19, 2025
Blood and breast cancer research highlights from the 67th American Society of Hematology Annual Meeting and Exposition, and the San Antonio Breast Cancer Symposium
June 11, 2024
This phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
September 30, 2021
This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
June 10, 2020
This phase II study is exploring the potent FLT3 inhibitor gilteritinib